Login to Your Account



ImClone Appears To Need New Trials; Samuel Waksal Resigns

By Randall Osborne


Thursday, May 23, 2002
In the wake of mixed study results disclosed at a scientific meeting, the refusal of its partner to retool overseas research as a way of helping dislodge the FDA-stalled cancer drug Erbitux, and disappointing first-quarter earnings, ImClone Systems Inc. reportedly plans to run several more trials in the U.S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription